How Modernity Made Us Allergic | NOEMA | Some Tesla engineers secretly started designing a Cybertruck alternative because they 'hated' the original concept, according to the new Elon Musk biography | Big pharma's blockbuster obesity drug battle is just getting started, and it's headed for $100 billion

View online | Unsubscribe (one-click). For inquiries/unsubscribe issues, Contact Us

You Might Like � � � � � � � � � Don't like ads? Go ad-free with TradeBriefs Premium How Modernity Made Us Allergic | NOEMA - NOEMA    Published by the Berggruen Institute Our very old immune systems can’t keep up with modern lifestyles and diets, leading to increases in all sorts of chronic health problems like allergies and obesity. Elizabeth, an engineer in her late-30s, has three children, all with some form of allergy. Her eldest daughter, Viola, 12, had eczema as a baby; has environmental allergies to pollen; and allergies to corn, tree nuts and peanuts. Continued here You Might Like � � � � � � � � � Some Tesla engineers secretly started designing a Cybertruck alternative because they 'hated' the original concept, according to the new Elon Musk biography - Business Insider    Some Tesla engineers weren't fans of Elon Musk's plans for the Cybertruck, the automaker's design chief Franz von Holzhausen told Walter Isaacson, whose biography on Musk comes out this week. "A majority of the people in this studio hated it," von Holzhausen said of the futuristic design, according to the book. "They were like, 'You can't be serious.' They didn't want to have anything to do with it. It was just too weird." Some Tesla engineers even took to covertly designing another version of the electric pickup after they saw a mock-up of the futuristic truck on display at SpaceX's showroom in Los Angeles during the summer of 2019, Isaacson, who shadowed Musk for three years, wrote. Continued here You Might Like � � � � � � � � � Big pharma's blockbuster obesity drug battle is just getting started, and it's headed for $100 billion - CNBC    In their most recent earnings reports, Novo Nordisk and Eli Lilly proved why they are the undisputed heavyweights in the prizefight for control of the rapidly growing weight-loss medications market. Beyond staggering sales figures for Novo's Ozempic and Wegovy and Lilly's Mounjaro, news of a study showing Wegovy can reduce the risk of heart disease and the anticipated approval of even more powerful prescription drugs to treat obesity will only strengthen the position of these venerable pharmaceutical giants, which have been in business for 100 years and 147 years, respectively. Even so, their competitors are not ceding the market to the current leaders. Pfizer, Amgen and other pharmaceutical companies are rushing to develop weight-loss drugs, though they may not be available for another year or more. "We think it's Novo and Lilly, and everyone else is just scrambling to keep up," said Emily Field, head of European pharmaceutical equity research at Barclays, which predicts a $100 billion global market for this class of drugs by around 2030. Since Wegovy and Mounjaro have been on the market, "neither company can make the drug fast enough," she said. "For both, demand has outpaced even their most bullish assumptions of what they're able to supply." Continued here

You Might Like � � �

�

�

�

�

�

�

You are receiving this mailer as a TradeBriefs subscriber. We fight fake/biased news through human curation & independent editorials. Your support of ads like these makes it possible. Alternatively, get TradeBriefs Premium (ad-free) for only $2/month If you still wish to unsubscribe, you can unsubscribe from all our emails here Our address is 309 Town Center 1, Andheri Kurla Road, Andheri East, Mumbai 400059 - 5179206